In this study, we evaluated the ability of anti-CD38 antibodies to kill tumor cells via ADCC, CDC, ADCP, and apoptosis induction in vitro against a panel of hematologic cancer cell lines, including the MM cell line NCI-H929, and other cell lines derived from various hematologic malignancies, including non-Hodgkin’s lymphoma (Daudi and Raji), Hodgkin’s lymphoma (L-1236), acute lymphocytic leukemia (Reh), and acute myeloid leukemia (MOLM-13). Here, CD38 is linked to hematologic disorder.